Key result
Anthracyclines and HER2 therapies can lead to HF, with doxorubicin carrying up to ~30% risk.
Population
Women diagnosed with breast cancer, including approximately 3,000,000 breast cancer survivors in the United…
Design
Review
Authors
Loading...
Highlights growing CV burden among breast cancer survivors; leaves open optimal cardio-oncology prevention strategies.
Highlights the growing population of breast cancer survivors and the need to address the cardiac implications of their treatments.
Unitt et al. (2014) conducted a review in Breast cancer and chemotherapy-induced cardiotoxicity. Anthracyclines and HER2 targeted therapies was evaluated. Anthracyclines and HER2-targeted therapies for breast cancer can lead to heart failure, with doxorubicin carrying up to a 30% risk of heart failure at cumulative doses greater than 500 mg/m2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: